Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m
Pharmaceutical technology | March 07, 2017
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.